Kayvan NIAZI,Adam LAZAR,Philip T. LIU,Annie SHIN,Peter SIELING
申请号：
US16622900
公开号：
US20200282037A1
申请日:
2018.06.15
申请国别(地区):
US
年份:
2020
代理人:
摘要：
A pharmaceutical compositions and methods for immunotherapy are provided. The pharmaceutical composition includes a genetically-engineered bacterium expressing a human disease-related antigen(s), preferably two or more patient-specific tumor antigens as a polytope. The bacterium has genetically engineered lipopolysaccharide or a patient's own endosymbiotic bacterium so that the bacterium expresses endotoxin at a low level, which is insufficient to induce a CD-14 mediated sepsis. The genetically-engineered bacterium can be administered to the patient, either systemically or locally, to induce tumor-specific immune response.
